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Because the human brain consumes a disproportionate fraction of the resting body’s energy, positron emission tomography (PET)
measurements of absolute glucose metabolism (CMRglc) can serve as disease biomarkers. Global mean normalization (GMN) of
PET data reveals disease-based diﬀerences from healthy individuals as fractional changes across regions relative to a global
mean. To assess the impact of GMN applied to metabolic data, we compared CMRglc with and without GMN in healthy awake
volunteers with eyes closed (i.e., control) against speciﬁc physiological/clinical states, including healthy/awake with eyes open,
healthy/awake but congenitally blind, healthy/sedated with anesthetics, and patients with disorders of consciousness. Without
GMN, global CMRglc alterations compared to control were detected in all conditions except in congenitally blind where regional
CMRglc variations were detected in the visual cortex. However, GMN introduced regional and bidirectional CMRglc changes at
smaller fractions of the quantitative delocalized changes. While global information was lost with GMN, the quantitative
approach (i.e., a validated method for quantitative baseline metabolic activity without GMN) not only preserved global CMRglc
alterations induced by opening eyes, sedation, and varying consciousness but also detected regional CMRglc variations in the
congenitally blind. These results caution the use of GMN upon PET-measured CMRglc data in health and disease.
1. Introduction
Noninvasive neuroimaging with positron emission tomog-
raphy (PET) and functional magnetic resonance imaging
(fMRI) provide the foundations of human brain mapping,
as practiced in the past four decades for PET and three
decades for fMRI [1–4]. Early PET studies concentrated
on quantitative imaging of resting-state blood ﬂow and
metabolism [2, 5], whereas later PET and then fMRI studies
used tools with some form of global mean normalization
Hindawi
Neural Plasticity
Volume 2018, Article ID 6120925, 16 pages
https://doi.org/10.1155/2018/6120925
(GMN), most notably statistical parametric mapping (SPM),
or the Scaled Subproﬁle Model of principal component anal-
ysis (SSM-PCA), to obtain regional diﬀerences among con-
trol and metabolically/functionally perturbed states. When
these methods are applied to PET metabolic radiotracers,
such as [18F]ﬂuorodeoxyglucose (FDG), the application of
these analysis tools often proceeded with the assumption that
global brain metabolic activity, deﬁned as the mean meta-
bolic rate of gray matter or the entire brain, is a valid basis
for normalization of regional values, in part because it is held
to facilitate group comparisons in the presence of physiolog-
ical and/or experimental intraindividual and interindividual
diﬀerences [6, 7]. GMN yields parametric images of frac-
tional or percentage diﬀerences from a variably deﬁned
global mean. While it is not a formal requirement for either
SPM or SSM-PCA, GMN has become an almost routine
and a necessary preparatory step in analyses of neuroimaging
data. For example, in the SSM-PCAmethod, the global eﬀects
are removed by log transformation and centering, but this
procedure has a similar eﬀect to GMN in that it removes
any scalar multiplicative parameters at the individual level.
Many PET studies exemplify the use of GMN to reveal diﬀer-
ences of cerebral metabolic rate of glucose (CMRglc) across
states of health and diﬀerent diseases. However, to validate
the metabolic diﬀerences, it is necessary to adequately
account for the substantial variability of resting metabolic
rates of human brain among individuals and brain states [8].
The covariance pattern extraction can be independent of
the normalization process on PET data. For example, SSM-
PCA analysis does not proceed as a form of GMN of the data.
Steps like log transformation and centering can, on certain
conditions, be used to remove scalar factors from the under-
lying disease patterns, which may be caused by variable
spatial covariance. Thus, it is important to diﬀerentiate uni-
variate assessment of CMRglc from voxel weights of disease
pattern derived as principal components of multivariate spa-
tial covariance. Eﬀects of absolute quantiﬁcation on SSM der-
ivation of disease-speciﬁc network proﬁles were reported by
Strother et al. [9] and more recently by Borghammer et al.
[10–14], who concluded that GMN can yield spurious inter-
pretations of perturbed measures of brain activity. Com-
monly used PCA analysis methods focus on regional
diﬀerences at the group level, beyond diﬀerences in global
brain function. However, we contest that analysis methods
which assume that global diﬀerences do not exist may cause
global eﬀects to contaminate “local” results, and thus, global
eﬀects should be separately evaluated to avoid this concern.
Several decades after the advent of PET, fMRI became the
common method of choice to detect functional diﬀerences
among brain regions and/or, diﬀerences between control
and patient groups, and for mapping of functional connectiv-
ity in resting brain [15]. The fMRI approach reveals resting-
state correlations of the somewhat poorly deﬁned regional
blood oxygenation level-dependent (BOLD) signal among
brain regions. Thus “functional connectivity networks” are
derived by searching for signiﬁcant correlations from the
spontaneous ﬂuctuations of the BOLD signal. However, the
BOLD signal itself is a nontrivial function of oxygen
extracted from the circulation and, therefore, reﬂects changes
in rates of both cerebral blood ﬂow (CBF) and oxidative
metabolism (CMRO2) [16]. Most analysis methods of
resting-state fMRI remove, among other variables, the
global BOLD signal to reveal the networks [17]. Results
are then inferred within these so-called resting-state net-
works from the remaining ﬂuctuations, where the amplitude
of the spontaneous BOLD signal is signiﬁcantly reduced
upon regression [17, 18]. In contrast, FDG-PET reveals
resting-state network activity by calculation of diﬀerences
among the regional CMRglc of a group of subjects or across
diﬀerent metabolic states, with subsequent application of
network analysis to the regions that diﬀer among groups
and/or conditions [19]. Most resting-state fMRI and PET
studies thus use some form of GMN prior to comparison
of the data for network determination. However, our focus
here is only the eﬀects of GMN upon PET imaging.
The validity of the GMNprocedure for creatingmetabolic
maps originally remained uncontested on the assumption
that most glucose and oxygen consumed in the resting-state
served “nonfunctional” mechanisms which are uncorrelated
with cognitive activity [20]. However, results from both early
and more recent studies challenge this assumption [18, 21].
The resting brain is the most energy-demanding organ in
the human body [22], the energy turnover due to Na+,K+-
ATPase function that sustains membrane repolarization and
ion gradient restoration for continuous neuronal activity
[23–25]. It is well accepted that energy demands of neuronal
activity in the resting awake human brain by far exceed the
magnitude of the additional energy turnover associated with
evoked or spontaneous changes of functional activity [26].
Yet, the fraction of the total metabolic rate altered by sponta-
neous or evoked events remains uncertain, and the extent to
which GMN obscures diﬀerences of the energy demand
across functional states thus still remains uncertain. In this
context, CBF and CMRO2 values measured in healthy
aging and in Parkinson’s disease show that conventional
GMN obscures evidence of metabolic changes in the brain
[27, 28]. Borghammer et al. showed that GMN of quanti-
tative PET-measured CBF measurements can yield false
positive ﬁndings of perfusion changes [10], but the
methods are nonetheless being generalized to metabolic
PET scans [29]. Borghammer et al. also demonstrated that
foci of elevated CBF attributed to small brain regions actu-
ally can arise as a consequence of normalization applied
only to gray matter [11]. In an examination of simulated
reduction of cortical metabolism, Borghammer et al. fur-
ther noted that GMN generally only recovered a few per-
cent of the original signal and conversely led to artifactual
ﬁndings of relative increases [12]. Thus, there are two
issues that potentially aﬀect the use of PET images as bio-
markers of disease; the raising of regional diﬀerences to
signiﬁcance and the removal of global diﬀerences among
individuals and groups that results from GMN.
Prompted by this evidence, we sought to test the hypoth-
esis that GMN may not only artiﬁcially raise minor regional
variations to signiﬁcance but also may signiﬁcantly obscure
global metabolic eﬀects when PET images of the resting brain
in speciﬁc disorders are compared. We used FDG-PET to
measure CMRglc at diﬀerent sites, where the control states
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(of resting healthy awake volunteers with eyes closed) were
compared to subjects in states established by conditions
ranging from normal sensory input to sedation by anesthesia
to diﬀerent clinical states. While some experiments involved
blood sampling of the FDG tracer’s supply to the brain, nec-
essary to obtain absolute values of CMRglc (aCMRglc), others
did not. To compare FDG-PET images from diﬀerent sites,
we developed a new method allowing quantitative measures
of CMRglc (qCMRglc) by a calibration procedure that is based
on comparison of qCMRglc data with aCMRglc data for a
control state (i.e., healthy awake with eyes closed). We then
validated the method, which is aimed for quantitative base-
line metabolic activity without GMN, by ﬁrst comparing
qCMRglc values found in control experiments from diﬀerent
sites and then comparing qCMRglc to aCMRglc for experi-
ments with blood sampling. We tested conditions that
included awake and eyes open states (presence of sensory
input), pharmacological intervention (anesthesia), disorders
of consciousness, and congenital blindness (clinical states),
in comparison to resting healthy awake subjects with eyes
closed (control). Comparison of t-maps of CMRglc without
GMN reveal heuristically important and pathognomonic
evidence of perturbations of brain metabolism across states
or among groups. However, GMN induced artiﬁcial relative
increases in states that are generally accepted as only induc-
ing metabolic decreases.
2. Materials and Methods
2.1. Subjects. Participants underwent tomography at four
sites, and imaging at each site included a control group.
FDG-PET measures were collected in a total of nine diﬀerent
resting states (Table 1) and compiled as anonymized data,
most of which previously had been published prior to the
present analysis. A group of healthy awake subjects imaged
with eyes closed (HAEC) was recorded at each site. Each
site’s HAEC served as control for the other groups recorded
at that site. There were 8 other groups: healthy awake subjects
with eyes open (HAEO) [30]; healthy subjects sedated with
1% desﬂurane (Des1%), 0.25% sevoﬂurane (Sev0.25%) [31],
or 0.5% sevoﬂurane (Sev0.5%); awake congenitally blind
(CB) subjects [32]; and patients with disorders of conscious-
ness, including unresponsive wakefulness syndrome (UWS),
minimally conscious state (MCS), and emergence from MCS
(EMCS) [33]. The diagnostic criteria for the selected disor-
ders of consciousness have been described earlier [34]. All
healthy participants were right-handed.
Among the ﬁve groups of healthy volunteers, two without
sedation (HAEC and HAEO) underwent tomography in
Munich, Germany, and those with sedation (Sev0.25%,
Sev0.5%, and Des1%) in Irvine, CA, USA. Among the four
groups with some form of disability, the CB underwent
tomography in Copenhagen, Denmark. All three groups with
disorders of consciousness had tomography in Liège, Belgium.
All tomograms were acquired upon obtaining written
informed consent from participants or from caregivers (in
the case of disorders of consciousness), in accordance with
the Helsinki Protocol, and all studies were approved by the
appropriate ethical review board per institution; the Ethics
Committee of the University Hospital of Liège (Belgium), the
Research Ethics Committee of the University of Copenhagen
and Frederiksberg (Denmark); the Institutional Review
Board at the University of California, Irvine (USA); and the
ethics review board of the Klinikum Rechts der Isar, Tech-
nische Universität München (Germany).
2.2. Tomography.All subjects underwent FDG-PET andMRI
scanning. Details of FDG-PET and MRI acquisition are
described in the original studies [30–34]. Brieﬂy, tomogra-
phies in USA and Denmark were performed on Siemens
ECAT high-resolution research tomographs (HRRT), in
Germany on a Siemens Biograph mMR PET/MRI, and in
Belgium on a Philips GEMINI TF PET/CT. Blood sampling
in USA subjects allowed calculation of absolute values of
CMRglc (aCMRglc) [31].
2.2.1. Tomography (Site Number 1). The two healthy groups
without any sedation, consisting of 11 HAEO subjects (aged
52± 10 years, 7 males) and 11 diﬀerent HAEC subject (aged
57± 10 years, 8 males; i.e., HAECGER), all used an MRI/
PET tomograph (Siemens Biograph mMR) at the Neuroim-
aging Center of Technical University of Munich, Germany
(Table 1). Subjects held their eyes closed or open depending
on their assigned group; details of the scans have been pub-
lished elsewhere [30]. Structural MRI data were acquired
(magnetization-prepared 180-degree radiofrequency pulses
and rapid gradient-echo (MP-RAGE), repetition time (TR)
2.3 s, echo time (TE) 2.98ms, 160 slices with 0.5mm gap,
256× 256mm ﬁeld of view (FOV), 256× 256 matrix size,
and 5 minutes and 3 seconds). About 30 minutes after the
bolus FDG injection, a 10-minute emission recording was
acquired (saturated list mode, 128 slices with 0.5mm gap,
192× 192mm matrix, and 3.7× 2.3× 2.7mm voxel).
2.2.2. Tomography (Site Number 2). The three sedated groups
(age range 18–22 years), consisting of 8 Sev0.25% subjects, 8
Sev0.5% subjects (same cases as Sev0.25%), and 7 Des1% sub-
jects, were all scanned using the Siemens ECAT high-
resolution research tomograph (HRRT) at the Department
of Anesthesiology of the University of California, Irvine,
California, USA, and also underwent MRI (Table 1). Details
of the tomographies of the Sev0.25% group, same as the
other groups, have been published elsewhere [31]. Two
intravenous catheters were inserted, one for arterialized
venous blood sampling and the other for FDG infusion
(203.5MBq) enabling measurement of absolute CMRglc. A
brief attenuation scan was obtained using a Cs-137 source,
and a ten-minute emission recording was obtained (207
slices at 1.2mm gap) beginning 32min after FDG applica-
tion; participants were still for the tracer uptake interval,
except when asked to perform a hand gesture as a test of
alertness/sedation. The tomograph had an eﬀective resolu-
tion of 3.3mm full width at half maximum (FWHM). Par-
ticipants had tomographies on diﬀerent occasions for the
selected doses of anesthetic gases, delivered with standard
calibrated vaporizers in 100% oxygen via a standard semicir-
cle breathing circuit using a Dräger AV anesthesia machine.
A Datex Ohmeda Capnomac Ultima (Helsinki, Finland) was
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used to monitor expired CO2 and anesthetic gas levels. This
HAEC group consisted of the participants who received 0%
sevoﬂurane (HAECsev; n = 8; Table 1) and 0% desﬂurane
(HAECdes; n = 7; Table 1).
2.2.3. Tomography (Site Number 3). PET data were acquired
in a group of 7 CB participants (three males aged 41± 8
years) and 7 HEAC (aged 25± 5 years, four males; HAEC-
DEN) using a Siemens ECAT HRRT at Rigshospitalet in
Copenhagen, Denmark (Table 1). Participants’ MRIs were
acquired using a 3T Siemens Trio MRI scanner at the Danish
Research Centre for Magnetic Resonance, Hvidovre Hospi-
tal, Hvidovre, Denmark. Details of the scans have been pub-
lished elsewhere [32]. One among the seven CB participants
had limited vision at birth that progressed to complete blind-
ness at the age of seven; all others were completely blind from
birth. Structural MRI data were acquired (MP-RAGE, TR
1.5 s, TE 3.93ms, inversion recovery time (TI) 0.8 s, 256 slices
with no gap, 192× 256mm FOV, and 6 minutes 36 seconds).
PET data were acquired forty minutes after bolus injection of
approximately 210MBq FDG (single frame, OSEM3Dmode,
207 slices with no gap, 1.2× 1.2× 1.2mm voxels, and 40
minutes). During the tracer uptake period, control partici-
pants were blindfolded and all participants rested in a dimly
lit room without falling asleep.
2.2.4. Tomography (Site Number 4). The groups with disor-
ders of consciousness consisted of (i) 49 UWS patients (aged
46± 16, 31 males; mean time since injury 1.7± 3.2 years), (ii)
65 MCS patients (aged 40± 16, 41 males; mean time since
injury 3.3± 4.3 years), and (iii) 17 EMCS patients (aged 35
± 15, 15 males; mean time since injury 3.0± 3.7 years). The
control group (HAECBEL) consisted of 28 participants (aged
44± 16, 16 males). All participants were scanned using the
Philips GEMINI TF PET/CT device at the University Hospi-
tal of Liege, Liege, Belgium (Table 1), according to proce-
dures described in detail elsewhere [33–35]. About 30min
after intravenous FDG injection, a single 12-minute emission
frame was recorded (90 slices with no gap, 256× 256 matrix,
and 2× 2× 2mm voxels). The control subjects were kept
awake in a dimly lit room during the FDG uptake, and all
patients were kept awake during FDG uptake.
2.3. Registration. All PET images were registered to the Mon-
treal Neurological Institute (MNI) space (3× 3× 3mm) using
a combination of linear and nonlinear registration tools on
publicly available platforms (i.e., advanced normalization
tools (ANTs) from http://stnava.github.io/ANTs, or Bio-
Image Suite from http://bioimagesuite.yale.edu). PET images
from Germany, USA, and Denmark were ﬁrst registered to
their corresponding MRI image using a rigid body transfor-
mation and then carried to the MNI template by computed
aﬃne and nonlinear transformations, with interpolation to
a 3× 3× 3mm3 voxel size. Belgian PET images were directly
registered to a common PET template created from the
HAECDEN group, using a combination of linear and nonlin-
ear registrations applying very restrictive and highly regular-
ized registration parameters.
2.4. Calibrating QuantiﬁedMeasures of CMRglc (qCMRglc).As
shown in Table 1, only the USA site had blood sampling data
to enable FDG-PET counts to be converted into “absolute
CMRglc” units of μmol/g/min (aCMRglc). To compare meta-
bolic measurements recorded from diﬀerent sites (where
blood sampling data were unavailable), we developed a new
method for calibrating quantiﬁed measures of CMRglc
(qCMRglc) that targets quantitative baseline metabolic activ-
ity without GMN. This method is based on the comparison
of qCMRglc data with aCMRglc data also for the HAEC con-
dition from Hyder et al. study (aCMRglc-HYD), with a mean
male age of 26.1± 3.8 years [36]. For consistency of the data
from the USA site with data from other sites, we also calcu-
lated qCMRglc for these ﬁve USA datasets, which in turn pro-
vided the validation for our procedure (see below).
Our goal was to preserve between-state global diﬀerences
in metabolism, which are believed to be removed by GMN.
Previous work has demonstrated that for identical conditions
(i.e., HAEC), region-to-region aCMRglc variation is propor-
tional to region-to-region PET radiation counts [37]. We
opted to apply per-site ﬁtting procedure by using the same
Table 1: Details of diﬀerent groups imaged at the various sites (Germany, USA, Denmark, and Belgium; see text for details).
PET imaging site Experimental group Control group
Site number 1, Germany (Technical University of Munich) HAEO (n = 11) HAECGER (n = 11)
Site number 2, USA (University of California, Irvine)
∗ Sev0.25% (n = 8) ∗ HAECsev (n = 8)∗ Sev0.5% (n = 8)
∗ Des1% (n = 7) ∗ HAECdes (n = 7)
Site number 3, Denmark (Rigshospitalet, Copenhagen University Hospital) CB (n = 7) HAECDEN (n = 7)
Site number 4, Belgium (University Hospital of Liege)
UWS (n = 65)
HAECBEL (n = 28)MCS (n = 65)
EMCS (n = 17)
∗ indicates that both absolute CMRglc (aCMRglc) and quantiﬁed CMRglc (qCMRglc) were obtained from the USA site, enabling comparison between them (see
Figures 1(b) and 1(c)). aCMRglc: absolute CMRglc with blood sampling of the tracer FDG supply to the brain; qCMRglc: calibration of quantiﬁed comparing
qCMRglc with aCMRglc for HAEC only eqs. (1 and 2); HAEC: healthy people awake with eyes closed (control condition); HAEO: healthy people awake with
eyes open; Des1%: healthy people sedated with 1% desﬂurane; Sev0.25%: healthy people sedated with 0.25% sevoﬂurane; Sev0.50%: healthy people sedated
with 0.5% sevoﬂurane; CB: awake people with congenital blindness; UWS: patients who were unresponsive wakefulness syndrome; MCS: patients who were
in a minimally conscious state; EMCS: patients who emerged from MCS.
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linear model for all individuals at a given site. Assuming
HAEC groups are comparable across sites [19], then this pro-
cedure would have the potential to compare metabolic diﬀer-
ences between states recorded at diﬀerent sites.
The “quantiﬁed CMRglc” metric, referred to as qCMRglc
to focus on quantitative baseline metabolic activity without
GMN, was obtained in two steps. First, a linear intensity
transformation of the original tissue radioactivity values
was computed on a per-site basis, such that the distribution
of voxels in the mean across the gray and white matter of
the cerebrum (excluding the cerebellum) from each site was
matched in intensity to the distribution of voxels from the
published aCMRglc-HYD database [36]. The similarity
between the distributions was calculated as the Jensen-
Shannon Divergence [38] (JSD), where the per-site linear
intensity transformation was calculated as the minimization
of the following expression:
JSD dist <aCMRglc −HYD > – dist asite · <FDGHAEC > +bsite ,
1
where dist (<aCMRglc−HYD>) and dist (<FDGHAEC>),
respectively, refer to the distribution of voxels in the mean
across the gray and white matter of the cerebrum (excluding
the cerebellum) of the published aCMRglc-HYD database
[36] and the original tissue-radioactivity values for each
HAEC group (FDGHAEC) from any site (Table 1), and asite
and bsite are, respectively, the resultant slope and intercept
from the ﬁt, unique for the speciﬁc site. Prior to minimiza-
tion of eq. (1), <FDGHAEC> was spatially smoothed to match
the point-spread function of <aCMRglc-HYD> as computed
by the 3dFWHMx program from the AFNI software package.
Then, the qCMRglc maps for each subject were computed by
applying the asite and bsite from eq. (1) as follows:
qCMRglc = asite · FDG + bsite, 2
where FDG refers to tissue-radioactivity concentrations from
any individual voxel for any single subject in any group and
only for the speciﬁc site for which asite and bsite were calcu-
lated. The calculated qCMRglc was used throughout this
study as ﬁtted between each site’s HAEC group and all other
groups from that site. The qCMRglc calculation was carried
out using the distributions of only intracranial voxels.
Two tests were run to validate qCMRglc. First, if compa-
rable qCMRglc values exist in HAEC groups from diﬀerent
sites, this would indicate that between-site comparisons
are possible. To test this, the mean qCMRglc within 41
gray matter regions (Table S1) drawn in the MNI reference
space was calculated for the ﬁve control groups (HAECDEN,
HAECGER, HAECsev, HAECdes, and HAECBEL) and
aCMRglc-HYD from Hyder et al. [36] that also represented
the HAEC condition. Pearson correlation and Euclidean
distance were calculated between the group means of
aCMRglc-HYD and qCMRglc in their respective 41 gray
matter regions repeated for each pair of groups. Then, p
values for statistical signiﬁcance were calculated with
permutation testing across the 41 gray matter regions with
1000 repetitions and rerunning the correlation and distance
calculations then taking the percentile of the actual
correlation/distance based on the randomly permuted
correlations/distances as a null distribution (one-sided test,
Pearson correlation higher than the null hypothesis and
Euclidean distance lower than the null hypothesis).
Second, as a further test of the ability to compare
qCMRglc between groups, we used aCMRglc data that was
available from the USA site. The Des1% and HAECdes groups
had the same subjects, as did the Sev0.25%, Sev0.5%, and
HAECsev groups. The same data were also used to calculate
qCMRglc (see above). Means of aCMRglc and qCMRglc were
calculated within each gray matter region across all subjects.
Treating the respective HAEC group as the x-axis and the
respective anesthetized group as the y-axis, a linear ﬁt was
calculated. The slopes from the linear ﬁts from aCMRglc were
compared to those from qCMRglc to establish the validity of
our calibration method.
2.5. Image Analysis. Mean qCMRglc maps were computed as
the voxel-by-voxel average across each group of subjects and
for the combined group of control subjects from all tomogra-
phy sites. Statistical t-maps were computed using an unpaired
voxel-wise two-sample two-tailed Student's t-test, assuming
equal variance for qCMRglc images following smoothing with
an 8mm Gaussian kernel. Statistical t-maps were also gener-
ated with the same parameters following GMN images, with
individual scaling to the whole-brain mean of qCMRglc. Sta-
tistics were computed both for qCMRglc and GMN images
using the gray matter regions (Table S1) for diﬀerence of
each state from the HAEC condition.
3. Results
3.1. Validating Quantiﬁed Measures of CMRglc (qCMRglc).
We compared the mean quantiﬁed estimates of CMRglc
(qCMRglc) across 41 gray matter regions for the ﬁve HAEC
groups listed in Table 1 to absolute CMRglc (aCMRglc) of
the HAEC group from Hyder et al. [36] (aCMRglc-HYD),
as shown in Figure 1(a). The Pearson correlation and Euclid-
ean distance between each pair of groups are listed in Table 2.
All correlations were highly signiﬁcant, and Euclidean dis-
tances were less than half of the mean in even one dimension,
despite there being 41 dimensions. Although HAECsev and
HAECdes correlated the highest because the subjects in
these groups overlapped, diﬀerent groups of subjects (e.g.,
HAECdes and HAECDEN or HAECsev and HAECDEN) had
similarly high correlation. We attribute the high correlation
among control subjects to the tight age group. The p values
resulting from comparing actual correlations and distances
to an artiﬁcially generated null distribution were zero (for
Pearson correlation, the value is higher than for 1000 random
permutations; for Euclidean distance, the value is lower than
for 1000 random permutations). The values indicate that all
HAEC groups, whether associated with aCMRglc or qCMRglc,
were highly similar in terms of both spatial extent (correla-
tion) and actual value (distance), conﬁrming that it is valid
to compare the HAEC groups from diﬀerent sites.
Figure 1(b) shows the linear ﬁt between the states of
anesthesia and respective control states using the aCMRglc
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estimates from site number 2, while Figure 1(c) shows the
same ﬁt for qCMRglc estimates where a slope of less than
1 in both Figures 1(b) and 1(c) corresponds to a lower
qCMRglc in the anesthetized group compared to the control
group. All linear ﬁts had R2 ≥ 0 95. The slopes of the linear
ﬁts were nearly identical for aCMRglc and qCMRglc (Des1%:
0.69 versus 0.68; Sev0.25%: 0.86 versus 0.84; and Sev0.5%:
0.79 versus 0.78). We also noted small but consistent shifts
of intercepts between the healthy awake and sedated, which
were reproducible for aCMRglc and qCMRglc (Des1%: 0.045
aCMRglc-HYD HAECdes HAECsev HAECGER HAECDEN HAECBEL
qCMRglc
aC
M
R g
lc
-H
YD
 o
r q
CM
R g
lc
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
1 4 5 6 7 8 9 10 11 13 17 18 19 20 21 22 23 24
Gray matter region
25 30 31 32 34 36 37 38 39 40 41 44 45 46 47 48 49 50 51 52 53 54 55
(a)
aC
M
R g
lc
D
es
1%
Se
v0
.2
5%
Se
v0
.5
%
Slope = 0.69
R
2 = 0.97
Slope = 0.86
R
2 = 0.99
Slope = 0.79
R
2 = 0.98
0.4
0.3
0.2
0.1
0.4
0.3
0.2
0.1
0.4
0.3
0.2
0.1
0.1 0.2
HAECdes
0.3 0.4 0.1 0.2
HAECsev
0.3 0.4 0.1 0.2
HAECsev
0.3 0.4
(b)
D
es
1%
Se
v0
.2
5%
Se
v0
.5
%
Slope = 0.78
R
2 = 0.98
Slope = 0.84
R
2 = 0.99
Slope = 0.68
R
2 = 0.95
0.4
0.3
0.2
0.1
0.4
0.3
0.2
0.1
0.4
0.3
0.2
0.1
0.1 0.2
HAECdes
0.3 0.4 0.1 0.2
HAECsev
0.3 0.4 0.1 0.2
HAECsev
0.3 0.4
qC
M
R g
lc
(c)
Figure 1: Validation of quantiﬁed CMRglc (qCMRglc). (a) Comparison of absolute CMRglc from Hyder et al. [36] (aCMRglc-HYD) with
qCMRglc from ﬁve sites for the HAEC condition (Table 1). Bars represent the mean across all subjects in each group for gray matter
regions (Table S1), where error bars are one standard deviation. All qCMRglc and aCMRglc-HYD values were very similar both relatively
between regions and in terms of mean value, suggesting across-site comparisons are possible with our procedure for quantiﬁed CMRglc.
The Pearson correlation and the Euclidean distance (Table 2) suggest high similarity and low diﬀerence of CMRglc for the HAEC group
across all sites. (b) Scatter plots, from left to right, for aCMRglc between Des1%, Sev0.25%, or Sev0.5% groups and equivalent HAEC
groups (Table 1). Each point is one gray matter region (Table S1). Slope and R2 from a linear ﬁt are shown, and units are μmol/g/min,
where a slope of less than 1 corresponds to a lower CMRglc in the anesthetized group compared to the control. (c) Same as in (b), except
using qCMRglc from each group. The slopes are almost identical in (b) and (c), indicating that the calculation of qCMRglc does not alter
the relationship between groups for aCMRglc.
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versus 0.062; Sev0.25%: 0.013 versus 0.024; and Sev0.5%:
0.011 versus 0.0.024). The largely consistent slope estimates
for aCMRglc and qCMRglc in Figures 1(b) and 1(c) demon-
strate that group-to-group diﬀerences present in aCMRglc
estimates were preserved after calculating qCMRglc.
3.2. qCMRglc across Diﬀerent States. Compared to the eyes
closed condition of the HAEC control group members
(0.31± 0.06μmol/g/min), the eyes open HAEO group mem-
bers had higher global estimates of qCMRglc (0.34
± 0.06μmol/g/min) and the CB members had similar global
gray matter estimates of qCMRglc (0.31± 0.05μmol/g/min),
as shown in Figure 2(a). The HAEO group members had
8–12% higher global qCMRglc estimates (0.34± 0.06μmol/
g/min) compared to themembers of the HAEC control group
in both gray and white matter regions (Figures S1A and S2A,
resp.). The qCMRglc diﬀerences between HAEC and HAEO
match reports of simple radiation counts [37]. In contrast,
members of the CB group revealed only insigniﬁcant
diﬀerences of global qCMRglc estimates across gray and
white matter regions, compared with members of the HAEC
groups (Figures S1B and S2B, resp.). Table 3 shows the
relationship of qCMRglc when comparing diﬀerent states to
the control condition as assessed by linear regression analysis
with intercept at zero (intercept = 0) and a ﬂoating intercept
(intercept ≠ 0). Compared to HAEC, decreasing slopes were
observed from HAEO to CB to Sev0.25% to Sev0.5% to
Des1% to EMCS to MCS to UWS in both gray and white
matter, and this pattern did not change with the regression
method. There were minimal diﬀerences in the slopes (less
than 16%) between the two regression methods except for
UWS, which also had the largest intercept (0.07 in gray
matter and 0.05 in white matter). The intercepts in all other
cases were much smaller in comparison, suggesting that
intercept at zero is a suﬃcient approximation for most of
the states examined (Figures S1 and S2).
Compared to HAEC controls, the groups of individuals
under sedation (Sev0.25%, Sev0.5%, and Des1%) had lower
global qCMRglc estimates (0.29± 0.06, 0.27± 0.05, and 0.27
± 0.05μmol/g/min in gray matter, respectively; Figure 2(b)).
Compared to the HAEC control group members, members
of the three sedation groups had 8–15% lower qCMRglc
estimates in gray matter (Figure S1C) and 8–12% lower
estimates in white matter (Figure S2C).
Compared to the HAEC group of control subjects,
patients with disorders of consciousness (UWS, MCS, and
EMCS) all had signiﬁcantly lower qCMRglc estimates (0.20
± 0.04, 0.19± 0.04, and 0.14± 0.02μmol/g/min in gray mat-
ter, resp.; Figure 2(c)). Compared to the HAEC control
group, the clinical states had 36–54% lower estimates of
qCMRglc in gray matter (Figure S1D) and 29–43% lower
estimates in white matter (Figure S2D).
3.3. Statistical t-Maps for qCMRglc and GMN Data across
States. Relative to the HAEC control group, the statistical
t-maps for the disorders of consciousness groups (UWS,
MCS, and EMCS), sedated groups (Des1%, Sev0.25%, and
Sev0.5%), healthy participants with eyes open group
(HAEO), and the group of congenitally blind subjects (CB),
respectively, are shown in Figures 3–6, respectively.
The UWS, MCS, and EMCS group members all had
global declines, judging from the qCMRglct-maps
(Figure 3(a)), consistent with the greatest decrease in subcor-
tical regions. In contrast, judged from the GMN t-maps, the
UWS, MCS, and EMCS group members had subcortical
hypometabolism, whereas other regions had relative hyper-
metabolism (Figure 3(b)). Compared to the MCS and EMCS
group members, the UWS group had areas of relative hyper-
metabolism in subcortical gray matter (Figure 3(b)).
The Sev0.25%, Sev0.5%, and Des1% groups all
showed global metabolic decrease in the qCMRglct-maps
(Figure 4(a)), with the Des1% group having less of a decline
in white matter than the Sev0.25% and Sev0.5% groups. In
contrast, using GMN t-maps, the Sev0.25%, Sev0.5%, and
Des1% groups all had a regional pattern of both hypometa-
bolism and hypermetabolism (Figure 4(b)). The Des1%
group had relative hypermetabolism of deep brain regions,
whereas the Sev0.25% and Sev0.5% groups had common
patterns of bidirectional change that were most pronounced
and of greatest spatial extent in the Sev0.5% group.
The HAEO group had diﬀuse global increases, estimated
from the qCMRglct-maps with the greatest increase in the
occipital cortex (Figure 5(a)), while GMN t-maps in contrast
showed relative white matter hypermetabolism and gray
Table 2: Results of quantiﬁed CMRglc (qCMRglc) from Figure 1(a), where HAEC groups from diﬀerent sites are compared to absolute CMRglc
from Hyder et al. [36] (aCMRglc-HYD). The upper triangular half is Pearson correlation (italicized), whereas the lower triangular half is
Euclidean distance (non-italicized). In the table p = 0 for all entries. The Pearson correlations were highly signiﬁcant, and all the Euclidean
distances were less than even one despite a total of 41 dimensions’ means. The high similarity between qCMRglc in the HAEC groups
measured at diﬀerent sites indicates that comparisons between sites are possible using our procedure for quantiﬁed CMRglc.
qCMRglc
aCMRglc-HYD HAECdes HAECsev HAECGER HAECDEN HAECBEL
aCMRglc-HYD 0.82 0.771 0.908 0.878 0.912
HAECdes 0.233 0.993 0.763 0.973 0.942
HAECsev 0.246 0.0401 0.712 0.956 0.905
qCMRglc HAECGER 0.213 0.202 0.228 0.851 0.876
HAECDEN 0.243 0.0851 0.11 0.154 0.946
HAECBEL 0.177 0.108 0.137 0.135 0.111
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matter hypometabolism, except in the visual cortex, which
had hypermetabolism (Figure 5(b)).
Only the CB group members had brain regions of both
metabolic increases and decreases (albeit of smaller magni-
tudes) in the qCMRglct-maps, with the increases mainly in
the visual cortex and the decreases beyond the visual cortex
(Figure 6(a)). This pattern was repeated when the GMN
t-maps revealed large domains of hypometabolic and hyper-
metabolic cortices, with vision areas showing the strongest
relative hypermetabolism (Figure 6(b)). While in the
qCMRglct-maps the hypometabolic (green in Figure 6(a))
and hypermetabolic (red in Figure 6(a)) regions revealed
homogenous activities, in the GMN t-maps the hypometa-
bolic (blue and green in Figure 6(b)) and hypermetabolic
(red and yellow in Figure 6(b)) regions showed heteroge-
neous activities.
The hot and cold colors in Figures 3–6 enabled visualiza-
tion of the eﬀect upon thresholding. However, we could not
apply the same statistical threshold across all conditions
because of large variation of groups’ sizes (Table 1). Thus, we
used thresholding as a means to reveal positive and negative
clusters with GMN versus qCMRglc images, when compared
to the control condition of eyes closed (Table 4). With disor-
ders of consciousness (Figure S3), for the qCMRglc images
there were only large-sized negative clusters (>98% of
voxels), whereas in GMN images there were many smaller-
sized negative (6–7% of voxels) and positive (0.1–14% of
voxels) clusters. With anesthesia sedation (Figure S4), for the
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Figure 2: Quantiﬁed CMRglc (qCMRglc) maps of the human brain across nine diﬀerent states (Table 1), which are (a) healthy awake sighted
people with eyes closed (HAEC) or with eyes open (HAEO), as well as healthy awake people who are congenitally blind (CB), (b) healthy
people under sedation with gaseous anesthetics (i.e., 0.25% sevoﬂurane (Sev0.25%), 0.5% sevoﬂurane (Sev0.5%), and 1% desﬂurane
(Des1%)), and (c) patients with disorders of consciousness (i.e., unresponsive wakefulness syndrome (UWS), minimally conscious state
(MCS), and emergence from minimally conscious state (EMCS)). Global increases in qCMRglc were observed proceeding from bottom to
top in each column, which is in general agreement with prior PET studies [19, 45–50, 53]. The units are in μmol/g/min. With HAEC as
the control condition, all other groups (except the CB group) showed signiﬁcant global diﬀerences in gray matter (Figure S1) and white
matter (Figure S2). These and all other images are in the coordinates of the MNI template: left column (from top to bottom) with z values
of −15mm, −12mm, and −39mm; middle column (from top to bottom) with z values of −6mm, −21mm, and −48mm; and right
column (from top to bottom) with z values of −3mm, −30mm, and −57mm.
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qCMRglc images there were only large-sized negative clusters
(71–96% of voxels), whereas in GMN images there were
many smaller-sized negative (0.2–13% of voxels) and
positive (0.3–11% of voxels) clusters. With eyes open in
awake/healthy (Figure S5), for the qCMRglc images there was
only one large-sized positive cluster (60% of voxels), whereas
in GMN images there were many smaller-sized negative
(2–20% of voxels) and positive (0.1–9% of voxels) clusters.
With congenitally blind (Figure S6), for the qCMRglc
images there was only one small-sized positive cluster and
two small-sized negative clusters (each 1% of voxels),
whereas in GMN images there was one large-sized negative
cluster (45% of voxels) and three smaller-sized positive
clusters (0.2–27% of voxels) clusters. In brief, the
thresholded t-maps showed that the number of positive/
negative clusters in the GMN images were much greater
(Table 4). Thus, all groups, except CB, had globally
unidirectional metabolic oﬀsets in qCMRglc t-maps, whereas
regionally bidirectional diﬀerences were seen for all groups
in GMN t-maps. In addition, the hypometabolism and
hypermetabolic regions identiﬁed by GMN t-maps depict
metabolic changes that are substantially smaller in
magnitude (i.e., 3–6 times) than the global diﬀerences
captured by the qCMRglct-maps (Figure S7).
4. Discussion
Absolute quantiﬁcation of brain glucose metabolism with
FDG-PET requires continuous arterial blood sampling
throughout the imaging procedure [1, 39]. As arterial blood
sampling in clinical settings is diﬃcult or logistically
impossible, alternative approaches are commonly used to
determine relative diﬀerences among groups or conditions.
The complementary approaches for quantitative PET gener-
ally involve a form of interindividual normalization, based on
the ratio of dose injected and body weight as a proportional
index of arterial input [40] or on the average uptake in whole
brain, gray matter, or a preselected reference region inside
[10] or outside [33] the brain. Moreover, there are consider-
ations of arterialized venous sampling [41, 42] and image-
derived input functions [43, 44]. The validity of any normal-
ization approach relies on speciﬁc assumptions that usually
are not readily testable, such as the linearity of the relation-
ship between body weight and distribution volume, the
expected range of metabolic changes (i.e., regional versus
global), or the validity of a chosen reference region for the
population being examined.
Here, we used a new validated method for deriving quan-
titative baseline metabolic activity from FDG-PET without
individual normalization [37], but where the quantiﬁed mea-
sure of CMRglc (qCMRglc) for the HAEC condition was com-
pared to the absolute CMRglc (aCMRglc) from Hyder et al.
(aCMRglc-HYD), also for the HAEC condition [36]. The pro-
cess consisted of two steps. First, an intensity transformation
was computed on a per-site basis for all HAEC datasets, using
the Jensen-Shannon divergence method [38], to match the
distribution of voxel intensities to the aCMRglc-HYD data-
base [36]. This enabled the original tissue-radioactivity
values for each HAEC group to be converted to aCMRglc
units on a per-site basis. This procedure also created a per-
site intensity transformation that maps the original PET
radioactivity counts to qCMRglc, which can be used to
Table 3: Relationship of quantiﬁed CMRglc (qCMRglc) in gray and white matter of the human brain, comparing diﬀerent states to the control
condition, as assessed by linear regression analysis with (intercept = 0) and without (intercept ≠ 0) an intercept at the origin. See Table 1 for
abbreviations of conditions. See Figures S1 and S2 for details on intercept = 0.
Intercept ≠ 0 Intercept = 0
HAEC versus Slope Intercept R2 Slope R2
Gray matter
HAEO 1.12 0.00 0.93 1.12 0.93
CB 0.87 0.03 0.87 0.97 0.89
Sev0.25% 0.87 0.02 0.98 0.92 0.98
Sev0.5% 0.79 0.02 0.98 0.85 0.97
Des1% 0.73 0.04 0.95 0.86 0.94
EMCS 0.54 0.03 0.8 0.64 0.83
MCS 0.49 0.04 0.73 0.6 0.78
UWS 0.26 0.07 0.65 0.46 0.73
White matter
HAEO 1.10 0.00 0.95 1.08 0.95
CB 0.90 0.02 0.92 0.98 0.93
Sev0.25% 0.88 0.01 0.99 0.99 0.92
Sev0.5% 0.81 0.01 0.98 0.88 0.98
Des1% 0.77 0.03 0.97 0.91 0.96
EMCS 0.61 0.02 0.81 0.71 0.84
MCS 0.59 0.02 0.73 0.69 0.77
UWS 0.35 0.05 0.64 0.57 0.73
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convert radioactivity values for other conditions (i.e., condi-
tions without lesions) scanned at that site using the same
scanning parameters into aCMRglc units. Finally, we vali-
dated this procedure by comparing qCMRglc to aCMRglc,
on a voxel-by-voxel basis using Pearson correlation and
Euclidean distance for all gray matter regions between the
two datasets.
Our goal was to compare glucose metabolism measured
by PET from a large number of conditions, including speciﬁc
levels of sedation depth induced by anesthesia, several levels
of disorder of consciousness, awake/healthy with eyes open,
and congenital blindness. Each cohort included a control
group of healthy, awake individuals resting with eyes closed,
which were all comparable across sites. The validated
qCMRglc group data led to new insights into the eﬀects of
GMN on the detection and interpretation of global versus
regional metabolic estimates.
The qCMRglc maps for all states (except the congenitally
blind) revealed signiﬁcant global diﬀerences relative to the
eyes closed control group, which ranged in magnitude from
~10% increase for the awake, eyes open group to ~60%
decrease in the unresponsive wakefulness syndrome. These
global changes of qCMRglc are in good agreement with previ-
ous ﬁndings of changes with eyes open versus eyes closed
states [45, 46], congenitally blind versus healthy sighted sub-
jects [47, 48], eﬀects of halogenated anesthetics [49–52], and
ﬁndings in disorders of consciousness [35, 53]. Speciﬁcally,
various anesthetics and disorders of consciousness have
largely reported globally depressed metabolism compared
to the healthy condition (see references within [19, 33]).
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Figure 3: Spatial distributions of metabolic variations in patients with disorders of consciousness (i.e., UWS, MCS, and EMCS in Figure 2(c))
versus the control group (i.e., HAEC in Figure 2(a)), shown with respect to unthresholded Student’s t-maps using (a) qCMRglc images and (b)
GMN images. (a) For the UWS,MCS, and EMCS groups, the unthresholded t-maps with qCMRglc indicated globally unidirectional metabolic
decreases in patients with disorders of consciousness. (b) But the unthresholded t-maps with GMN demonstrated the presence of regionally
bidirectional metabolic changes in disorders of consciousness. Based on validation of qCMRglc to aCMRglc-HYD (Figures 1 and 2; Table 2),
without GMN the global decreases corresponded to about 0.15 μmol/g/min (UWS<MCS≈EMCS) and with GMN the global changes were
diminished to put overemphasis on the regional diﬀerences. See Figure S3 for thresholded maps (Table 4).
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After GMN, these large global changes were absent from
the GMN t-maps due to regression to the mean value. Con-
sequently, the GMN t-maps showed patterns of regional
increase and decrease in metabolism among diﬀerent states,
suggesting that signiﬁcant global information is not cap-
tured with the GMN procedure. Although increases/
decreases were observed in congenitally blind with/without
GMN, both the hypometabolic and hypermetabolic regions
showed heterogeneous activities upon GMN. These results
suggest that global normalization puts an overemphasis on
regional diﬀerences.
4.1. GMN Eliminates Global Metabolic Changes across States.
In all conditions other than congenitally blind, we found
globally unidirectional changes of qCMRglc estimates
compared to the control group, with metabolic diﬀerences
among states distributed within a large range (i.e., 0.14 to
0.34μmol/g/min). In sharp contrast, GMN yielded regional
increases and decreases compared to the eyes closed control
group, with relative metabolic rate diﬀerences among states
distributed within a narrow range (i.e., ±0.05μmol/g/min).
These results suggest that the global component of FDG-
PET images contains state-dependent metabolic information
that is lost upon GMN. Moreover, the present work shows
that the hypometabolism and hypermetabolic regions
revealed by GMN depict metabolic changes that are sub-
stantially smaller in magnitude than the inherent global
metabolic diﬀerences. Although the regional pattern of devi-
ations from the global mean of normalized FDG conveys
important information about metabolic networks, exclusion
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Figure 4: Spatial distributions of metabolic variations with sedation (i.e., Des1%, Sev0.25%, and Sev0.5% in Figure 2(b)) versus the control
group (i.e., HAEC in Figure 2(a)), shown with respect to unthresholded Student’s t-maps using (a) qCMRglc images and (b) GMN images.
(a) For Des1%, Sev0.25%, and Sev0.5% groups, the unthresholded t-maps with qCMRglc indicated globally unidirectional metabolic
decreases with sedation. (b) However, the unthresholded t-maps with GMN depicted regions with metabolic increases and decreases upon
sedation. Based on validation of qCMRglc to aCMRglc-HYD (Figures 1 and 2; Table 2), without GMN the global decreases corresponded to
about 0.05μmol/g/min (Des1%≈ Sev0.5%< Sev1%) and with GMN the deemphasis on global changes put the focus on the regional
diﬀerences. See Figure S4 for thresholded maps (Table 4).
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of the global mean can yield diﬀerent interpretations such as
the regionally increased metabolic activity to disease states, a
concern previously raised in the context of neurodegenera-
tive diseases [12, 54].
However, when absolute diﬀerences are of small magni-
tude and regionalized, as in the present comparison of con-
genitally blind to the sighted control group, images with
and without GMN showed very similar patterns of hypome-
tabolism and hypermetabolic areas. In this particular case,
the GMN procedure exposed the diﬀerences only after
removal of interindividual global variations, without any
penalty for misrepresentation of the magnitude of the diﬀer-
ences. Overall, these comparisons, especially with that of the
congenitally blind group versus the other groups, strongly
suggest that there are new insights to be gained by inclusion
of both absolute and GMN analysis for PET-FDG data of
neuropsychiatric and neurodegenerative diseases.
4.2. Study Limitations and Future Directions. The main limi-
tation of the current study is the acquisition of PET-FDG
images from multiple sites that were calibrated to produce
qCMRglc comparisons across the diﬀerent groups, thereby
limiting the statistical signiﬁcance of state-dependent varia-
tions. The high similarity between qCMRglc in the resting
awake eyes closed (control) state across ﬁve diﬀerent sites,
which were nearly identical to aCMRglc region-to-region var-
iations, suggests that qCMRglc maps from the diﬀerent sites
indeed were comparable. While the qCMRglc measure proved
stable on a per-group basis, this report did not investigate its
validity on a per-subject basis, speciﬁcally for conditions with
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Figure 5: Spatial distributions of metabolic variations with healthy participants with eyes open (i.e., HAEO in Figure 2(a)) versus the eyes
closed control group (i.e., HAEC in Figure 2(a)), shown with respect to unthresholded Student’s t-maps using (a) qCMRglc images and (b)
GMN images. (a) For the HAEO group, the unthresholded t-maps with qCMRglc indicated the presence of globally unidirectional
metabolic increases with eyes open. (b) Conversely, the unthresholded t-maps with GMN revealed regions of increased and decreased
metabolism with eyes open. Based on validation of qCMRglc to aCMRglc-HYD (Figures 1 and 2; Table 2), without GMN the global
increases corresponded to about 0.05μmol/g/min while with GMN, the global changes were minute. See Figure S5 for thresholded maps
(Table 4).
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Figure 6: Spatial distributions of metabolic variations in the congenitally blind (i.e., CB in Figure 2(a)) versus the eyes closed control group
(i.e., HAEC in Figure 2(a)), shown with respect to unthresholded Student’s t-maps using (a) qCMRglc images and (b) GMN images. (a) For the
CB group, the unthresholded t-maps with qCMRglc images indicated both regions with increased and decreased metabolism in association
with blindness. Unidirectional metabolic decreases were observed in CB in most regions other than visual areas. (b) Similarly, the
unthresholded t-maps with GMN indicated regionally bidirectional metabolic changes with blindness and unidirectional metabolic
increases were observed in regions associated with vision. Based on validation of qCMRglc to aCMRglc-HYD (Figures 1 and 2; Table 2),
with and without GMN the global changes were essentially negligible. There were increases/decreases in visual/nonvisual areas, either with
or without GMN. See Figure S6 for thresholded maps (Table 4).
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brain lesions. Future FDG-PET studies quantiﬁed with arte-
rial sample inputs can improve aCMRglc estimates to reduce
the intersubject variation among groups. Notwithstanding
this conclusion, the present qCMRglc estimates had excellent
correlations among all ﬁve control groups in this study.
In the brain regions least vulnerable to eﬀects of partial
volume eﬀects (i.e., regions deﬁned by wide swathes of
cortex with net spillover to and from adjacent tissues
due to the inherent spatial smoothness of PET data is
low), gray matter qCMRglc exceeded the estimates in
white matter by 2–3-fold for the control state, in good
agreement with prior studies [19, 55, 56]. However, dif-
ferent magnetic resonance spectroscopy (MRS) methods
(e.g., 17O MRS, 31P MRS, 13C MRS) and calibrated fMRI
can be used to obtain absolute maps of CMRglc or CMRO2
across these tissues for further validation [57].
Another concern of this study is the small sample sizes
in three out of four sites and which limited the types of
image analysis techniques we could employ. Variations in
the Pearson correlation and the Euclidean distance for
comparing across the control groups could be due to the
multicenter data being heterogeneous (e.g., data acquired
with diﬀerent PET cameras). This and other weaknesses
of the study limit the validity of the qCMRglc method
for imaging others brain disorders (e.g., Alzheimer’s dis-
ease and Parkinson’s disease) at this stage, and thus, this
procedure could be considered if aCMRglc comparisons
are made for groups imaging across diﬀerent brain states
and/or PET scanners.
As noted above, qCMRglc for gray and white matter is
sensitive to partial volume eﬀects because the thickness of
the cerebral cortex is close to the spatial resolution delivered
by current PET instruments [58]. Higher spatial resolution,
such as that from the Siemens HRRT used to acquire FDG-
derived images in the USA and Denmark sites, as well as
improved MRI-based detection of cortical thickness, will
provide better partial volume correction [59], propagating
to increased accuracy of global versus regional metabolic dif-
ferences measured across disease states. Using an HRRT
scanner with suﬃcient resolution to measure the PET signal
from the human globus pallidus, Borghammer et al. [14]
employed reference cluster normalization to report that only
the globus pallidus showed signiﬁcant hypermetabolism in
Parkinson’s disease. A review of 2-deoxy-glucose studies of
rodent and nonhuman primate models of Parkinson’s dis-
ease showed that the globus pallidus most consistently
reported true hypermetabolism [60]. Subsequent studies
have dealt with the issue of normalization as raised by Bor-
ghammer et al. [14]. Dhawan et al. [61] reported that the spa-
tial covariance pattern was not induced by reductions in
global activity, opposing Borghammer et al. [14], whereas
Dukart et al. [62] examined usefulness of diﬀerent normali-
zation procedures, and their ﬁndings do not contradict Bor-
ghammer et al. [14]. Since the sample sizes in some of our
groups were small, we could not compare the results from
diﬀerent types of normalization methods (e.g., reference
cluster and data-driven) and instead chose to compare
eﬀects on PET data with and without GMN.
Based on our results, and previous work, we thus caution
that comparing any disease with the healthy condition
should not begin with the assumption that global changes
do not exist or, if they do exist, that they are not relevant to
alterations in brain function (and behavior). We observed
global changes across the entire brain without GMN in nearly
all the states examined herein, but with GMN, these global
changes were diminished showing bidirectional changes in
all conditions examined. In one condition, the global changes
appeared quite similar with and without GMN, but there was
Table 4: Thesholding t-maps in Figures 3–6 revealed unidirectional and bidirectional changes, which is illustrated in terms of the number of
positive (P) and negative (N) clusters, where they, respectively, correspond to areas of higher and lower intensities compared to control. See
Table 1 for abbreviations of conditions. The positive clusters in the thresholded GMN (PGMN) versus qCMRglc (PqCMR) t-maps were 8 times
greater, whereas negative clusters in the thresholded GMN (NGMN) versus qCMRglc (NqCMR) t-maps were 2 times greater. Similarity between
thresholded GMN and qCMRglct-maps was assessed by several metrics: (i) the total number of clusters given by the sum of P and N clusters,
for qCMRglc (TqCMR = PqCMR + NqCMR) and GMN (TGMN = PGMN + NGMN) thresholded t-maps; (ii) the diﬀerence between the P clusters (DP)
for GMN and qCMRglc thresholded t-maps (DP = PGMN − PqCMR); (iii) the diﬀerence between the N clusters (DN) for GMN and qCMRglc
thresholded t-maps (DN = NGMN −NqCMR). Analysis shows that TGMN was about 4 times greater than TqCMR, whereas both DP and DN
were greater than 0, signifying that GMN thresholded t-maps consistently revealed more bidirectional changes. For thresholded t-maps,
see Figure S3 for EMCS, MCS, and UWS versus control (HAEC); Figure S4 for Sev0.25, Sev0.5, and Des1 versus control (HAEC);
Figure S5 for HAEO versus control (HAEC); and Figure S6 for CB versus control (HAEC).
Condition versus control Threshold (t-value)
Number of clusters Similarity between GMN and qCMRglc
PqCMR NqCMR PGMN NGMN TqCMR TGMN DP DN
EMCS 4 0 1 2 1 1 3 2 0
MCS 4 0 1 5 1 1 6 5 0
UWS 4 0 1 2 1 1 3 2 0
Sev0.25% 2 0 1 1 2 1 3 1 1
Sev0.5% 2 0 1 0 4 1 4 0 3
Des1% 2 0 1 2 3 1 5 2 2
HAEO 1 1 0 3 2 1 5 2 2
CB 0.5 1 2 3 1 3 4 2 −1
Mean ± standard deviation 0.3± 0.5 1.0± 0.5 2.3± 1.5 1.9± 1.1 1.3± 0.7 4.1± 1.1 2.0± 1.4 0.9± 1.4
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no assumption made about global or regional changes
despite both analysis methods revealing nearly the same
regional changes. Existing statistical analysis methods can
undermine the relevance of global changes. For example,
the Gaussian random ﬁeld theory is optimized to detect small
spatial regions of activity diﬀerences, deﬁning “signal” as a
limited spatial region whereas “noise” is deﬁned as the back-
ground in large swathes of tissue. Also, if the global mean is
used as a nuisance variable in techniques such as analysis of
covariance, global changes will, by deﬁnition, be obscured.
While our current work is focused on univariate analysis, if
one includes the global signal as a “covariate of no interest,”
it does not matter whether the analysis is univariate or mul-
tivariate, the procedure still eﬀectively removes global eﬀects.
For example, if the total signal (and underlying neuronal
activity) from all brain regions were reduced by a factor of
2, both univariate and multivariate analysis would conclude
no diﬀerence across regions, unless an absolute measure of
the global component was included. The basic idea that the
global signal should not be discarded applies to both univar-
iate and multivariate analysis. Thus, to adequately measure
signal versus noise in global as well as regional brain metab-
olism with the highest level of conﬁdence, higher-sensitivity
imaging methods are needed in combination with diﬀerent
statistical analysis methods, which are beyond the scope of
the current work and are issues for future studies.
5. Conclusions
At present, analysis of PET data generally ignores the global
baseline signal. However, both the baseline neuronal activity
and the requisite energy demands supporting the activity of
the cerebral cortex of awake humans are substantial [25, 26,
63]. Removing the global PET signal prior to comparison
with the resting awake eyes closed (control) state exposed
regionally bidirectional metabolic eﬀects, along with some
regional changes observed upon normalization. Improper
use of global signal normalization may thus lead to the incor-
rect assignment of elevated metabolism to regions and, by
inference, the presence of elevated neuronal activity despite
an impaired state of consciousness. Conversely, the approach
used here (i.e., without GMN) not only preserved the global
alteration caused by sedation and consciousness disorders
but also detected localized abnormalities in the context of
the congenitally blind. In light of the current ﬁndings, we rec-
ommend that the baseline metabolic activity be included in
the analysis of PET neuroimaging data, and only then is it
possible to discern global and regional metabolic diﬀerences
between healthy and diseased states.
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